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Introduction
Despite their limited licensed indications, anti-IL1 agents
are often used in real-life practice for an increasing num-
ber of diseases. A national survey to record the off-label
use of this class of therapeutics in France was started in
January 2011. The survey is coordinated by the French
National Reference Centre for Auto-inflammatory
Diseases, under the aegis of the “Club Rhumatisme et
Inflammation”.
Objectives
The survey aims at gathering information concerning:
the number of patients treated with anti-IL1 agents in
France, the treated disease, the kind and the indication
of the used anti-IL1 agents, their efficacy and safety.
Methods
We set up a physician-directed questionnaire covering
the following areas: patient data, disease data, anti-IL1
agent (molecule, dose and frequency), its efficacy,
adverse events. Any adult or paediatric patient who had
received an anti-IL1 agent from January 2005 in France
could be included.
Results
At two years 193 patients from 37 centres have been
included. Demographic data: 104 males, 89 females;
141 adult, 52 paediatric patients, mean age 35.2 years
at treatment onset. Main diseases were: adult onset
Still disease (AoSD) (35), systemic onset juvenile idio-
pathic arthritis (SoJIA) (29), gout (27), anakinra-treated
CAPS (22), mevalonate kinase deficiency (MKD) (14),
familial Mediterranean fever (FMF) (12), SAPHO
syndrome (9), Schnitzler’s syndrome (7). The main off-
label used agent was anakinra, used at least once in
189 patients. Canakinumab was used in 25 patients,
mainly children, in most cases as a second-line treat-
ment after anakinra. Rilonacept is not yet available in
France. 83 patients (66 anakinra, 17 canakinumab trea-
ted patients) were still on treatment at last visit. Some
form of clinical response was found in 90% of ana-
kinra-treated patients. A complete physician-evaluated
response was reported in Schnitzler’s syndrome (85%),
gout (80%), CAPS (75%), AoSD (59%), FMF (50%),
SoJIA (42%), MKD (30%), SAPHO (11%). 83% of cana-
kinumab-treated patients showed clinical response. At
least one adverse event (AE) was reported for 53% and
a serious adverse event (SAE) for 10% of anakinra trea-
ted patients. Main AEs were: injection site reactions
(48%), weight gain (11%) and liver enzymes elevation
(9%). SAEs were principally severe infections, macro-
phage activation syndrome and severe hepato-toxicity.
50% of patients treated with canakinumab showed an
AE, namely respiratory infections and liver anomalies.
Only few patients had a SAE (severe infections).
Conclusion
Anakinra is the main off-label anti-IL1 agent used in
France, showing partial to complete efficacy in most
patients; complete clinical response rates vary according
to specific diseases, being higher in Schnitlzler syndrome,
gout, CAPS and AoSD. Around half of the patients
showed at least one AE, mainly related to a poor local
tolerance. Preliminary data of our survey suggest that
canakinumab was efficacy and well tolerate in most
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